UNIGE document Scientific Article
previous document  unige:750  next document
add to browser collection

Bortezomib-induced skin eruption

Sanchez-Politta, S.
Kerl, K.
Published in Dermatology. 2008, vol. 216, no. 2, p. 156-8
Abstract Bortezomib (Velcad) is a proteasome inhibitor recently developed and mainly used for the treatment of multiple myeloma. Bortezomib represents a novel class of drugs functioning as proteasome inhibitors. Skin complications of bortezomib treatment are very frequent but poorly characterized. We describe the case of a patient who developed erythematous and edematous plaques after treatment with bortezomib. This case illustrates one of the potential reactions associated with bortezomib administration and underlines the need to recognize and report cutaneous side effects of this new drug.
Keywords Antineoplastic Agents/administration & dosage/adverse effectsBiopsyBoronic Acids/administration & dosage/adverse effectsDiagnosis DifferentialDose-Response Relationship DrugDrug Eruptions/etiology/pathologyHumansMaleMiddle AgedMultiple Myeloma/drug therapyPyrazines/administration & dosage/adverse effectsSkin/pathology
PMID: 18216478
Full text
Research group Immunothérapie des cancers (42)
(ISO format)
SANCHEZ-POLITTA, S. et al. Bortezomib-induced skin eruption. In: Dermatology, 2008, vol. 216, n° 2, p. 156-8. https://archive-ouverte.unige.ch/unige:750

182 hits



Deposited on : 2009-02-11

Export document
Format :
Citation style :